Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: An open question

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages

  Reis, Leonardo Oliveira ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; CABAZITAXEL; DIETHYLSTILBESTROL; DOCETAXEL; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; BIOAVAILABILITY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMORBIDITY; ETHNIC DIFFERENCE; HUMAN; ORCHIECTOMY; PROSTATE CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 84862641659     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0040     Document Type: Review

References (34)

1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360 103-106. (doi:10.1016/ S0140-6736(02)09408-4)
2. Chodak GW 1989 Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma. Urology 33 42-44. (doi:10.1016/0090- 4295(89)90105-2)
3. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y &Fukui I 2008 Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. BJU International 101 1096-1100. (doi:10.1111/j.1464-410X.2007.07374.x)
4. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC & South African Triptorelin Study Group 2003 Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU International 92 226-231. (doi:10.1046/j.1464-410X.2003.04308.x)
5. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B et al. 2006 Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology 24 3984-3990. (doi:10.1200/JCO.2006.06.4246)
6. Kaisary AV, Tyrrell CJ, Peeling WB & Griffiths K 1991 Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. British Journal of Urology 67 502-508. (doi:10.1111/ j.1464-410X.1991.tb15195.x)
7. Lawrentschuk N, Fernandes K, Bell D, Barkin J & Fleshner N 2011 Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. Journal of Urology 185 848-854. (doi:10.1016/j.juro.2010.10.055)
8. Marberger M, Kaisary AV, Shore ND, Karlin GS, Savulsky C, Mis R, Leuratti C & Germa JR 2010 Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, International Multicenter Study. Clinical Therapeutics 32 744-757. (doi:10.1016/ j.clinthera.2010.04.013)
9. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED & Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New England Journal of Medicine 341 1781-1788. (doi:10.1056/ NEJM199912093412401)
10. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L & Catalán R 2007 Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Journal of Urology 178 1290-1295. (doi:10.1016/j.juro.2007.05.129)
11. Morote J, Planas J, Salvador C, Raventós CX, Catalán R &Reventós J 2009 Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU International 103 332. (doi:10.1111/j.1464-410X.2008.08062.x)
12. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D & Resnick MI 2000 Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 56 1021. (doi:10.1016/S0090-4295(00)00793- 7)
13. Perachino M & Cavalli V 2008 Testosterone (T) level correlates with survival in pts with advanced prostate cancer (APC): the lower is really the better. Journal of Urology 179 179. (doi:10.1016/S0022-5347(08)60520-0)
14. Perachino M, Cavalli V & Bravi F 2010 Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU International 105 648. (doi:10.1111/j.1464-410X.2009.08814.x)
15. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO & Grignon D 2005 Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - long term results of phase III RTOG85-31. International Journal of Radiation Oncology, Biology, Physics 61 1285-1290. (doi:10.1016/j.ijrobp.2004. 08.047)
16. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 1491. (doi:10.1016/S0140-6736(00)02163-2)
17. Reis LO 2011 Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology [in press]. (doi:10.1007/s12032-011- 9991-z;PMID:21626233)
18. Reis LO, Vieira LF, Zani EL, Denardi F, de Oliveira LC &Ferreira U 2010 Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer. Journal of Investigative Medicine 58 957-960. (doi:10.231/JIM. 0b013e3181f5d610)
19. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L & Schwartz M 1997 Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of Clinical Oncology 15 2928-2938. (Pubitemid 27330021)
20. Schmitt B, Bennett C, Seidenfeld J, Samson D & Wilt T 2000 Maximal androgen blockade for advanced prostate cancer. Cochrane Database of Systematic Reviews 2 CD001526. (doi:10.1002/14651858.CD001526)
21. Scholz M, Lam R, Strum S, Jennrich R, Johnson H & Trilling T 2007 Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Urology 70 506-510. (doi:10.1016/ j.urology.2007.04.015)
22. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL & Wilt TJ 2000 Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of Internal Medicine 132 566-577. (Pubitemid 30171897)
23. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB & Stein B 1996 Leuprorelin acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clinical Therapeutics 18 647. (doi:10.1016/S0149-2918(96)80215-3)
24. Silva ED, Ferreira U, Matheus W, Faria EF, Silva GD &Saito M 2012 Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. International Urology and Nephrology [in press]. (doi:10.1007/s11255- 012-0134-z;PMID:22315155)
25. Smith MR 2007 Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clinical Cancer Research 13 241. (doi:10.1158/1078-0432. CCR-06-2086)
26. Smith M & McGovern F 2001 Gonadotropin releasing hormone agonist failure in a man with prostate cancer. Journal of Urology 166 211. (doi:10.1016/S0022- 5347(05)66115-0)
27. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T et al. 2008 Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Journal of Urology 180 921-927. (doi:10.1016/j.juro. 2008.05.045)
28. Tanaka N, Fujimoto K, Hirao Y, Shimizu K, Tsujimoto S &Samma S 2007 Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer. Archives of Andrology 53 289. (doi:10.1080/01485010701601222)
29. Tombal B 2005 Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone. European Urology Supplements 4(5) 14-19. (doi:10.1016/j.eursup.2005.04.004)
30. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, Caplan RJ & Kennealey GT 1995 Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 46 220-226. (doi:10.1016/S0090-4295(99) 80197-6)
31. Wheeler MJ, D'Souza A, Matadeen J & Croos P 1996 Ciba Corning ACS: 180 testosterone assay evaluated. Clinical Chemistry 42 1445.
32. Wilke TJ & Utley DJ 1987 Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and otherwise normal women with altered binding of sex-hormone binding globulin. Clinical Chemistry 33 1372.
33. Yri OE, Bjoro T & Fossa SD 2006 Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. European Urology 49 54. (doi:10.1016/j.eururo.2005.09.009)
34. Zherdev AV, Byzova NA, Izumrudov VA & Dzantiev BB 2003 Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples. Analyst 128 1275. (doi:10.1039/b303288d)